Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Holdings -- Ignore unavailable to you. Want to Upgrade?

To: Richard Strutz who wrote (174)	7/15/1999 5:22:00 PM
From: William Whitehead Jr.	Read Replies (1) \| Respond to of 224

Time to kick this puppy into overdrive! CLINICAL TRIAL OF BIOTECH HOLDINGS' DIABETES DRUG, DIAB II, Completed in Brazil VANCOUVER, British Columbia, July 15 /PRNewswire/ -- Robert B. Rieveley, President of Biotech Holdings Ltd. ("Biotech") (OTC Bulletin Board: BIOHF), is pleased to announce that a clinical trial of Biotech's Type II Diabetes drug, DIAB II, has been completed in Brazil. The purpose of the clinical trial is to provide supplementary information for a regulatory application for approval of DIAB II in Brazil as a prescription treatment for Type II or Adult-Onset Diabetes. The trial was carried out by one of the largest independent contract research laboratories in Brazil, working with a Brazilian endocrinologist specializing in diabetes. Trial design was reviewed by Biotech and by Biobras S.A. Biobras, formerly a subsidiary of Eli Lilly and now the fourth largest insulin manufacturer in the world, is Biotech's licensee for marketing and distribution of DIAB II in Brazil. Results from the clinical trial are now being analyzed in preparation for completing the regulatory filing in Brazil. Trial results will be announced in a timely manner. The trial in Brazil was initiated earlier this year to supplement and confirm results of a prior clinical trial in China. The trial in China, involving three hospitals and 60 doctors, demonstrated the safety and efficacy of DIAB II and led to the approval of DIAB II by regulators in that country as a prescription treatment for both Type II Diabetes and Impaired Glucose Tolerance, a condition that frequently precedes a diagnosis of diabetes. DIAB II, an oral diabetes drug is an insulin-receptor sensitizer, a new class of drugs for controlling the chronically high blood sugar level that typifies diabetes. DIAB II works by improving the patient's ability to utilize both endogenous and injected insulin, the hormone that regulates blood sugar levels. Type II Diabetes affects more than 150 million people worldwide, including 15 million people in the United States and over 20 million in Latin America. Biotech Holdings Ltd. is based in Vancouver, British Columbia and has its laboratory and plant facility in Richmond, B.C. Biotech Holdings trades on the Over the Counter Bulletin Board in the United States (OTC Bulletin Board symbol: BIOHF) and on the Alberta Stock Exchange (ASE symbol: BIO). For inquiries, contact Austin Rand at Biotech Holdings Ltd. 1-888-216-1111 (toll-free), 8 a.m. to 5 p.m. Pacific time, or by e-mail at biotech@direct.ca. For further information, please visit Biotech's website at biotechltd.com.